Back to search results

Toripalimab（JS001） as Monotherapy in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors

Abroad (travel likely)RecruitingPHASE2

Conditions

Solid Tumor · Advanced Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Cancer center of Sun Yat-sen University, Guangzhou, Guangdong, China

    Contact: Study coordinator (Zhi-da Lv, BS) · lvzd@sysucc.org.cn · +862087342635
    Contact: Principal Investigator (Rui-hua Xu, MD, PhD)
    Contact: Principal Investigator (Feng Wang, MD, PhD)
    Contact: Principal Investigator (Ying Jin, MD)

  • The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou, China

    Contact: Study coordinator (WeiWei Chen, M.D.) · 33054905@qq.com · +86 085186512900

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Contact: Study coordinator (Liu Huang, M.D.) · huangliu017@163.com · 027-69378822

  • The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China

    Contact: Study coordinator (Jinghua Sun, M.D.) · sunjinghua2008@hotmail.com · +86 0411-84671291
Study leads

  • Rui-hua Xu, MD, PhD

    Principal Investigator

    Sun Yat-Sen University Cancer Center

  • FENG WANG, MD,PhD

    Principal Investigator

    Sun Yat-Sen University Cancer Center

  • Ying Jin

    Principal Investigator

    Sun Yat-Sen University Cancer Center

View source on ClinicalTrials.gov(opens in a new tab)